Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2020 Apr 8;8(1):e000347corr1. doi: 10.1136/jitc-2019-000347corr1

Correction: Phase 2 study of pembrolizumab in patients with advanced rare cancers

PMCID: PMC7254116  PMID: 32269144

Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J ImmunoTher Cancer 2020;8:e000347. doi: 10.1136/jitc-2019-000347

In the article titled 'Phase 2 study of pembrolizumab in patients with advanced rare cancers', the author name Abulrahman Abonofal is spelt incorrectly. The correct spelling is Abdulrahman Abonofal.


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES